Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 31

1.

EGFR variant-mediated invasion by enhanced CXCR4 expression through transcriptional and post-translational mechanisms.

Rahimi M, George J, Tang C.

Int J Cancer. 2010 Apr 15;126(8):1850-60. doi: 10.1002/ijc.24964.

2.
3.

High chemokine receptor CXCR4 level in triple negative breast cancer specimens predicts poor clinical outcome.

Chu QD, Panu L, Holm NT, Li BD, Johnson LW, Zhang S.

J Surg Res. 2010 Apr;159(2):689-95. doi: 10.1016/j.jss.2008.09.020. Epub 2008 Oct 16.

PMID:
19500800
4.

Chemokine receptors in advanced breast cancer: differential expression in metastatic disease sites with diagnostic and therapeutic implications.

Cabioglu N, Sahin AA, Morandi P, Meric-Bernstam F, Islam R, Lin HY, Bucana CD, Gonzalez-Angulo AM, Hortobagyi GN, Cristofanilli M.

Ann Oncol. 2009 Jun;20(6):1013-9. doi: 10.1093/annonc/mdn740. Epub 2009 Feb 23.

5.

p38 MAP kinase controls EGF receptor downregulation via phosphorylation at Ser1046/1047.

Adachi S, Natsume H, Yamauchi J, Matsushima-Nishiwaki R, Joe AK, Moriwaki H, Kozawa O.

Cancer Lett. 2009 May 8;277(1):108-13. doi: 10.1016/j.canlet.2008.11.034. Epub 2009 Jan 12.

PMID:
19138820
6.

[Chemokine receptor CXCR4 gene silencing with shRNA inhibits breast cancer metastasis to the lung in nude mice].

Zhang MX, Han N, Yu SY, Leng Y.

Zhonghua Zhong Liu Za Zhi. 2008 May;30(5):325-9. Chinese.

PMID:
18953828
8.

CXCR4 membrane expression in node-negative breast cancer.

Blot E, Laberge-Le Couteulx S, Jamali H, Cornic M, Guillemet C, Duval C, Hellot MF, Pille JY, Picquenot JM, Veyret C.

Breast J. 2008 May-Jun;14(3):268-74. doi: 10.1111/j.1524-4741.2008.00573.x. Epub 2008 Mar 26.

PMID:
18373506
9.

Modulation of survival pathways in ovarian carcinoma cell lines resistant to platinum compounds.

Benedetti V, Perego P, Luca Beretta G, Corna E, Tinelli S, Righetti SC, Leone R, Apostoli P, Lanzi C, Zunino F.

Mol Cancer Ther. 2008 Mar;7(3):679-87. doi: 10.1158/1535-7163.MCT-07-0450.

10.

Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function.

Massarweh S, Osborne CK, Creighton CJ, Qin L, Tsimelzon A, Huang S, Weiss H, Rimawi M, Schiff R.

Cancer Res. 2008 Feb 1;68(3):826-33. doi: 10.1158/0008-5472.CAN-07-2707.

11.

Expression of EGFR variant vIII promotes both radiation resistance and hypoxia tolerance.

Weppler SA, Li Y, Dubois L, Lieuwes N, Jutten B, Lambin P, Wouters BG, Lammering G.

Radiother Oncol. 2007 Jun;83(3):333-9. Epub 2007 May 23.

PMID:
17512071
12.

Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer.

Cabioglu N, Gong Y, Islam R, Broglio KR, Sneige N, Sahin A, Gonzalez-Angulo AM, Morandi P, Bucana C, Hortobagyi GN, Cristofanilli M.

Ann Oncol. 2007 Jun;18(6):1021-9. Epub 2007 Mar 9.

PMID:
17351259
13.

Soluble VCAM-1 and E-selectin in breast cancer: relationship with staging and with the detection of circulating cancer cells.

Silva HC, Garcao F, Coutinho EC, De Oliveira CF, Regateiro FJ.

Neoplasma. 2006;53(6):538-43.

PMID:
17167725
14.

Hypophosphorylation of residue Y1045 leads to defective downregulation of EGFRvIII.

Han W, Zhang T, Yu H, Foulke JG, Tang CK.

Cancer Biol Ther. 2006 Oct;5(10):1361-8. Epub 2006 Oct 26.

PMID:
16969069
15.

Molecular detection of EGFRvIII-positive cells in the peripheral blood of breast cancer patients.

Silva HA, Abra├║l E, Raimundo D, Dias MF, Marques C, Guerra C, de Oliveira CF, Regateiro FJ.

Eur J Cancer. 2006 Oct;42(15):2617-22. Epub 2006 Sep 7.

PMID:
16956761
16.
17.

Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer.

Andre F, Cabioglu N, Assi H, Sabourin JC, Delaloge S, Sahin A, Broglio K, Spano JP, Combadiere C, Bucana C, Soria JC, Cristofanilli M.

Ann Oncol. 2006 Jun;17(6):945-51. Epub 2006 Apr 20.

PMID:
16627550
18.
19.

Chemokine receptor CXCR4 expression in breast cancer as a potential predictive marker of isolated tumor cells in bone marrow.

Cabioglu N, Sahin A, Doucet M, Yavuz E, Igci A, O Yildirim E, Aktas E, Bilgic S, Kiran B, Deniz G, Price JE.

Clin Exp Metastasis. 2005;22(1):39-46.

PMID:
16132577
20.

CCR7 and CXCR4 as novel biomarkers predicting axillary lymph node metastasis in T1 breast cancer.

Cabioglu N, Yazici MS, Arun B, Broglio KR, Hortobagyi GN, Price JE, Sahin A.

Clin Cancer Res. 2005 Aug 15;11(16):5686-93.

Supplemental Content

Support Center